182 related articles for article (PubMed ID: 35152768)
1. Sclerotherapy for Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
Thiele B; Abdel-Aty Y; Marks L; Lal D; Marino M
Ann Otol Rhinol Laryngol; 2023 Jan; 132(1):82-90. PubMed ID: 35152768
[TBL] [Abstract][Full Text] [Related]
2. Complications from office sclerotherapy for epistaxis due to hereditary hemorrhagic telangiectasia (HHT or Osler-Weber-Rendu).
Hanks JE; Hunter D; Goding GS; Boyer HC
Int Forum Allergy Rhinol; 2014 May; 4(5):422-7. PubMed ID: 24431220
[TBL] [Abstract][Full Text] [Related]
3. Injection of bevacizumab and cyanoacrylate glue for hereditary hemorrhagic telangiectasia.
Khoueir N; Borsik M; Camous D; Herman P; Verillaud B
Laryngoscope; 2019 Oct; 129(10):2210-2215. PubMed ID: 31566760
[TBL] [Abstract][Full Text] [Related]
4. Office-based sclerotherapy for recurrent epistaxis due to hereditary hemorrhagic telangiectasia: a pilot study.
Boyer H; Fernandes P; Duran O; Hunter D; Goding G
Int Forum Allergy Rhinol; 2011; 1(4):319-23. PubMed ID: 22287439
[TBL] [Abstract][Full Text] [Related]
5. Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis.
Esteban-Casado S; Martín de Rosales Cabrera AM; Usarralde Pérez A; Martínez Simón JJ; Zhan Zhou E; Marcos Salazar MS; Pérez Encinas M; Botella Cubells L
Laryngoscope; 2019 Oct; 129(10):2216-2223. PubMed ID: 30908653
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Timolol in a Novel Intranasal Thermosensitive Gel for Hereditary Hemorrhagic Telangiectasia-Associated Epistaxis: A Randomized Clinical Trial.
Peterson AM; Lee JJ; Kallogjeri D; Schneider JS; Chakinala MM; Piccirillo JF
JAMA Otolaryngol Head Neck Surg; 2020 Nov; 146(11):1006-1014. PubMed ID: 32940653
[TBL] [Abstract][Full Text] [Related]
7. Prospective randomized trial of sclerotherapy vs standard treatment for epistaxis due to hereditary hemorrhagic telangiectasia.
Boyer H; Fernandes P; Le C; Yueh B
Int Forum Allergy Rhinol; 2015 May; 5(5):435-40. PubMed ID: 25643928
[TBL] [Abstract][Full Text] [Related]
8. Laser-Assisted Control of Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Systematic Review.
Abiri A; Goshtasbi K; Maducdoc M; Sahyouni R; Wang MB; Kuan EC
Lasers Surg Med; 2020 Apr; 52(4):293-300. PubMed ID: 31441079
[TBL] [Abstract][Full Text] [Related]
9. Health-Related Quality of Life Outcome Measures in Individuals With Hereditary Hemorrhagic Telangiectasia: A Scoping Review.
Gong AJ; Garg T; Khalil A; Gowda PC; Mathai SC; Rowan NR; Merlo CA; Weiss CR
Am J Rhinol Allergy; 2024 Jan; 38(1):60-76. PubMed ID: 37855028
[TBL] [Abstract][Full Text] [Related]
10. Sclerotherapy Versus Cautery/Laser Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia.
Woodard TD; Yappel-Sinkko KB; Wang X; McCrae KR; Parambil JG
Laryngoscope; 2022 May; 132(5):920-925. PubMed ID: 34160081
[TBL] [Abstract][Full Text] [Related]
11. Prospective pilot study of Floseal® for the treatment of anterior epistaxis in patients with hereditary hemorrhagic telangiectasia (HHT).
Lee JM; Wu V; Faughnan ME; Lasso A; Figol A; Kilty SJ
J Otolaryngol Head Neck Surg; 2019 Oct; 48(1):48. PubMed ID: 31615556
[TBL] [Abstract][Full Text] [Related]
12. The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
Albarki H; Rimmer J
Am J Rhinol Allergy; 2022 Nov; 36(6):890-896. PubMed ID: 35929049
[TBL] [Abstract][Full Text] [Related]
13. Duration of effectiveness of coblation for recurrent epistaxis in hereditary hemorrhagic telangiectasia.
Feller CN; Adams JA; Friedland DR; Poetker DM
Am J Otolaryngol; 2022; 43(3):103409. PubMed ID: 35216850
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab as Treatment for Epistaxis in Hereditary Hemorrhagic Telangiectasia: A Literature Review.
Kini SD; Yiu DW; Weisberg RA; Davila JF; Chelius DC
Ann Otol Rhinol Laryngol; 2019 May; 128(5):467-471. PubMed ID: 30693788
[TBL] [Abstract][Full Text] [Related]
15. Effect of Topical Intranasal Therapy on Epistaxis Frequency in Patients With Hereditary Hemorrhagic Telangiectasia: A Randomized Clinical Trial.
Whitehead KJ; Sautter NB; McWilliams JP; Chakinala MM; Merlo CA; Johnson MH; James M; Everett EM; Clancy MS; Faughnan ME; Oh SP; Olitsky SE; Pyeritz RE; Gossage JR
JAMA; 2016 Sep; 316(9):943-51. PubMed ID: 27599329
[TBL] [Abstract][Full Text] [Related]
16. [Bevacizumab: a new success in hereditary hemorrhagic telangiectasia].
Bennesser Alaoui H; Lehraiki M; Hamaz S; El Attar N; Fakhreddine N; Serraj K
Rev Med Interne; 2015 Sep; 36(9):623-5. PubMed ID: 25595875
[TBL] [Abstract][Full Text] [Related]
17. Hereditary hemorrhagic telangiectasia-related epistaxis: innovations in understanding and management.
Sautter NB; Smith TL
Int Forum Allergy Rhinol; 2012; 2(5):422-31. PubMed ID: 22566463
[TBL] [Abstract][Full Text] [Related]
18. Understanding hereditary hemorrhagic telangiectasia: From genetic anomalies to systemic manifestations, quality of life, and epistaxis management-Exploring the otolaryngologist's integral role.
Hayama M; Maeda Y; Obata S; Tsuda T; Takeda K; Nishida T; Inohara H
Auris Nasus Larynx; 2024 Apr; 51(2):305-312. PubMed ID: 38008660
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab for Epistaxis in Hereditary Hemorrhagic Telangiectasia: An Evidence-based Review.
Halderman AA; Ryan MW; Marple BF; Sindwani R; Reh DD; Poetker DM
Am J Rhinol Allergy; 2018 Jul; 32(4):258-268. PubMed ID: 29745243
[TBL] [Abstract][Full Text] [Related]
20. TIMolol nasal spray as a treatment for epistaxis in hereditary hemorrhagic telangiectasia (HHT) - Study protocol of the prospective, randomized, double-blind, controlled cross-over TIM-HHT trial.
Andorfer KEC; Seebauer CT; Koller M; Zeman F; Berneburg M; Fischer R; Vielsmeier V; Bohr C; Kühnel TS
Clin Hemorheol Microcirc; 2022; 80(3):307-315. PubMed ID: 34864649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
